Leerink Partnrs Weighs in on Marinus Pharmaceuticals, Inc.’s Q1 2024 Earnings (NASDAQ:MRNS)

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) – Investment analysts at Leerink Partnrs lifted their Q1 2024 EPS estimates for shares of Marinus Pharmaceuticals in a report released on Monday, April 15th. Leerink Partnrs analyst M. Goodman now forecasts that the biopharmaceutical company will post earnings per share of ($0.61) for the quarter, up from their previous estimate of ($0.64). The consensus estimate for Marinus Pharmaceuticals’ current full-year earnings is ($2.29) per share. Leerink Partnrs also issued estimates for Marinus Pharmaceuticals’ Q2 2024 earnings at ($0.48) EPS, Q3 2024 earnings at ($0.35) EPS, Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.70) EPS, FY2025 earnings at ($0.75) EPS, FY2026 earnings at ($0.05) EPS, FY2027 earnings at $0.20 EPS and FY2028 earnings at $0.65 EPS.

Other equities research analysts have also recently issued research reports about the stock. Oppenheimer restated a “market perform” rating and issued a $9.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, March 7th. StockNews.com cut shares of Marinus Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, March 6th. Cantor Fitzgerald reiterated an “overweight” rating and set a $28.00 price target on shares of Marinus Pharmaceuticals in a research report on Wednesday, April 10th. HC Wainwright reiterated a “buy” rating and set a $27.00 price target on shares of Marinus Pharmaceuticals in a research report on Tuesday. Finally, Truist Financial lowered their price target on shares of Marinus Pharmaceuticals from $25.00 to $10.00 and set a “buy” rating for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, three have given a hold rating and four have given a buy rating to the company. According to data from MarketBeat.com, Marinus Pharmaceuticals currently has a consensus rating of “Hold” and a consensus target price of $16.07.

Marinus Pharmaceuticals Trading Down 2.1 %

MRNS opened at $1.38 on Thursday. The company has a current ratio of 4.07, a quick ratio of 4.01 and a debt-to-equity ratio of 5.68. The stock has a market capitalization of $75.80 million, a PE ratio of -0.52 and a beta of 0.91. Marinus Pharmaceuticals has a 1-year low of $1.11 and a 1-year high of $11.26. The firm has a 50-day moving average price of $8.37 and a two-hundred day moving average price of $8.36.

Marinus Pharmaceuticals (NASDAQ:MRNS) last posted its quarterly earnings data on Tuesday, March 5th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, missing the consensus estimate of ($0.64) by ($0.10). The company had revenue of $7.19 million during the quarter, compared to analyst estimates of $7.78 million. Marinus Pharmaceuticals had a negative net margin of 456.31% and a negative return on equity of 269.75%. During the same quarter in the previous year, the business posted ($0.76) EPS.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the company. Vanguard Group Inc. grew its holdings in Marinus Pharmaceuticals by 3.7% during the fourth quarter. Vanguard Group Inc. now owns 2,673,231 shares of the biopharmaceutical company’s stock valued at $29,058,000 after purchasing an additional 95,756 shares during the period. Wellington Management Group LLP grew its holdings in Marinus Pharmaceuticals by 54.8% during the fourth quarter. Wellington Management Group LLP now owns 241,299 shares of the biopharmaceutical company’s stock valued at $2,623,000 after purchasing an additional 85,455 shares during the period. Barclays PLC grew its holdings in Marinus Pharmaceuticals by 747.4% during the fourth quarter. Barclays PLC now owns 76,372 shares of the biopharmaceutical company’s stock valued at $830,000 after purchasing an additional 67,360 shares during the period. Nuveen Asset Management LLC grew its holdings in Marinus Pharmaceuticals by 1.1% during the fourth quarter. Nuveen Asset Management LLC now owns 139,752 shares of the biopharmaceutical company’s stock valued at $1,519,000 after purchasing an additional 1,475 shares during the period. Finally, Royal Bank of Canada grew its holdings in Marinus Pharmaceuticals by 124.1% during the fourth quarter. Royal Bank of Canada now owns 15,364 shares of the biopharmaceutical company’s stock valued at $167,000 after purchasing an additional 8,507 shares during the period. Institutional investors and hedge funds own 98.80% of the company’s stock.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.